title: [Cyclosporin A in the treatment of Eaton-Lambert myasthenic syndrome].
abstract: The Lambert-Eaton myasthenic syndrome (LEMS) is a disorder of he cholinergic neurotransmition at the presinaptic terminal of the neuromuscular junction. Clinically it is characterized by muscular weakness, hyporeflexia and autonomic dysfunction. In this entity thet presence of antibodies against calcium channels impair acetylcholine release. Whe used cyclosporin-A in a patient with LEMS and this resulted in a complete clinical and neurophysiological recovery after four months of therapy.
authors.affiliation: Departamento de Medicina Interna, Universidad de Navarra, Pamplona.
authors.forename: J R
authors.initials: JR
authors.lastname: Yuste Ara
authors.forename: O
authors.initials: O
authors.lastname: Beloqui Ruiz
authors.forename: J
authors.initials: J
authors.lastname: Artieda Gonzalez-Granda
authors.forename: J I
authors.initials: JI
authors.lastname: Herrero Santos
authors.forename: A
authors.initials: A
authors.lastname: De la Peña Fernandez
authors.forename: J
authors.initials: J
authors.lastname: Prieto Valtueña
mesh_terms: D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use*; D004576:Electromyography; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015624:Lambert-Eaton Myasthenic Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D008875:Middle Aged; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine
vernacular_title: Ciclosporina-A como tratamiento del síndrome miasteniforme de Eaton-Lambert.